Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 8 | 12 |
| 2004 | 4 | 3 | 7 |
| 2005 | 6 | 13 | 19 |
| 2006 | 3 | 7 | 10 |
| 2007 | 7 | 7 | 14 |
| 2008 | 6 | 6 | 12 |
| 2009 | 4 | 7 | 11 |
| 2010 | 6 | 10 | 16 |
| 2011 | 10 | 14 | 24 |
| 2012 | 6 | 5 | 11 |
| 2013 | 8 | 10 | 18 |
| 2014 | 18 | 16 | 34 |
| 2015 | 22 | 22 | 44 |
| 2016 | 15 | 19 | 34 |
| 2017 | 16 | 8 | 24 |
| 2018 | 17 | 18 | 35 |
| 2019 | 15 | 26 | 41 |
| 2020 | 18 | 20 | 38 |
| 2021 | 12 | 11 | 23 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 4 | 5 |
| 2024 | 8 | 11 | 19 |
| 2025 | 16 | 7 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatr Blood Cancer. 2025 Dec; 72(12):e32046.
-
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025 Oct; 646(8084):462-473.
-
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res. 2025 Jul 01; 31(13):2639-2654.
-
Gene context drift identifies drug targets to mitigate cancer treatment resistance. Cancer Cell. 2025 Sep 08; 43(9):1608-1621.e9.
-
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol. 2025 Jun 21; 27(5):1341-1355.
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
-
Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025 Aug; 25(8):613-633.